Prognosis
Regeneron Cocktail Wins Nod for Use to Prevent Covid-19
- FDA clears first antibody treatment for use before infection
- Scope is widened to include at-risk and unvaccinated people
This article is for subscribers only.
Regeneron Pharmaceuticals Inc.’s antibody treatment for Covid-19 received U.S. regulators’ blessing as the first preventative therapy for unvaccinated and immunocompromised people in high-risk settings.
The decision by the Food and Drug Administration expands an emergency use authorization, first granted in November, for the antibody cocktail to treat mild to moderate Covid infections in people 12 years old and up. It allows Regeneron to offer the combination of casirivimab and imdevimab, called REGEN-COV, in more contexts to more patients in the same age group. The treatment still hasn’t been cleared for patients hospitalized with Covid.